

**Form 7
MONTHLY PROGRESS REPORT
September 2014**

Name of CSE Issuer: **Highmark Marketing Inc. (the "Issuer")**
Trading Symbol: **HMK**
Number of Outstanding Listed Securities: **13,368,607 common shares and 1,977,282 reserved for issuance**
Date: **October 6, 2014**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On September 15, 2014 the Issuer announced that BCBud Producers Inc. ("BCBud") received a letter from Health Canada confirming receipt of BCBud's application to become a licensed producer of marijuana pursuant to the Marihuana for Medical Purposes Regulations (the "MMPR"). The Issuer had previously announced on Aug. 6, 2014, the terms of a share exchange agreement among the Issuer, BCBud and Blue Moon Advertising Inc. ("Blue Moon") to acquire 100 % of the authorized share capital of BCBud from its shareholder, Blue Moon.

2. Provide a general overview and discussion of the activities of management.

The Issuer established a science division named MJ Bioscience, headed up by Dr. D. Yevtushenko. BCBUD advised the Issuer that it received a letter from Health Canada confirming receipt of its application to become a licensed producer of marijuana pursuant to the MMPR.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Issuer announced that its cannabis R&D division, now named MJ Bioscience, has received a research plan from Dr. Yevtushenko, PhD.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

On September 4, 2014, PRC Partners Ltd. received 300,000 common shares of the Issuer in forgiveness of \$135,000 of debt owed by the Issuer for consulting services for business development in Europe provided by PRC from June to August of 2014.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **October 6, 2014**

Marc Branson

Name of Director or Senior Officer

"Marc Branson"

Signature

Chief Executive Officer & a Director

Official Capacity

Issuer Details		
Name of Issuer: Highmark Marketing Inc.	For Month End September 2014	Date of Report: YYYYMMDD 2014/10/06
Issuer Address: Suite 800, 1199 West Hastings Street		
City/Province/Postal Code: Vancouver, BC V6E 3T5	Issuer Fax No.: 888.241.5996	Issuer Telephone No. 604.630.8760
Contact Name: Marc Branson	Contact Position: CEO	Contact Telephone No. 604.630.8760
Contact Email Address: info@highmarkcorp.ca	Web Site Address: highmarkcorp.ca	